Vincent Pons

Quebec, QC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Herpes Simplex Virus 1 Infection Does Not Increase Amyloid-β Pathology in APP/PS1 Mice.

Herpes Simplex Virus 1 Infection Does Not Increase Amyloid-β Pathology in APP/PS1 Mice.

Journal: Journal of Alzheimer's disease : JAD
Published: December 25, 2023

Author Correction: Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis.

Author Correction: Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis.

Journal: Experimental & molecular medicine
Published: February 24, 2023

Muramyl Dipeptide Administration Delays Alzheimer's Disease Physiopathology via NOD2 Receptors.

Muramyl Dipeptide Administration Delays Alzheimer's Disease Physiopathology via NOD2 Receptors.

Journal: Cells
Published: June 02, 2022

Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis.

Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis.

Journal: Experimental & molecular medicine
Published: May 18, 2022

Multifocal Cerebral Microinfarcts Modulate Early Alzheimer's Disease Pathology in a Sex-Dependent Manner.

Multifocal Cerebral Microinfarcts Modulate Early Alzheimer's Disease Pathology in a Sex-Dependent Manner.

Journal: Frontiers in immunology
Published: November 11, 2021

Triggering Innate Immune Receptors as New Therapies in Alzheimer's Disease and Multiple Sclerosis.

Triggering Innate Immune Receptors as New Therapies in Alzheimer's Disease and Multiple Sclerosis.

Journal: Cells
Published: July 20, 2021

Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease.

Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease.

Journal: Pharmacological reviews
Published: May 17, 2021

Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer's disease.

Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer's disease.

Journal: Alzheimer's research & therapy
Published: October 21, 2020

The Intellicage system provides a reproducible and standardized method to assess behavioral changes in cuprizone-induced demyelination mouse model.

The Intellicage system provides a reproducible and standardized method to assess behavioral changes in cuprizone-induced demyelination mouse model.

Journal: Behavioural brain research
Published: October 12, 2020

Microglia Purinoceptor P2Y6: An Emerging Therapeutic Target in CNS Diseases.

Microglia Purinoceptor P2Y6: An Emerging Therapeutic Target in CNS Diseases.

Journal: Cells
Published: June 08, 2020

Beneficial Roles of Microglia and Growth Factors in MS, a Brief Review.

Beneficial Roles of Microglia and Growth Factors in MS, a Brief Review.

Journal: Frontiers in cellular neuroscience
Published: May 20, 2020

Role of Macrophage Colony-Stimulating Factor Receptor on the Proliferation and Survival of Microglia Following Systemic Nerve and Cuprizone-Induced Injuries.

Role of Macrophage Colony-Stimulating Factor Receptor on the Proliferation and Survival of Microglia Following Systemic Nerve and Cuprizone-Induced Injuries.

Journal: Frontiers in immunology
Published: November 04, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026